Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969534). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Severe Immune-Related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/fulltext

Pembrolizumab Versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1606774

Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext

Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of At Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-67362100228-2/fulltext

Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression https://ascopost.com/issues/may-10-2021/cemiplimab-rwlc-for-first-line-treatment-of-nsclc-with-high-pd-l1-expression/

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1801005

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1810865

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC https://www.nejm.org/doi/10.1056/NEJMoa1716948

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC https://www.jto.org/article/S1556-0864(21)02322-4/fulltext

First-Line Nivolumab plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1910231

FDA Approves Nivolumab plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression ≥1%) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1

Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors (ICI) in Advanced Non-Small Cell Lung Cancer (aNSCLC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9048?af=R

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064

Durvalumab plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) https://clinicaltrials.gov/ct2/show/NCT05060016